Navigation Links
Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
Date:11/26/2013

SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at two investor conferences next week.  

On December 3 at 2:15pm Eastern Time (11:15am Pacific Time) he will make a presentation at the Deutsche Bank 2013 Biofest in Boston. 

On December 4 at 11:30am Eastern Time (8:30am Pacific Time) he will make a presentation at the 25th Annual Piper Jaffray Healthcare Conference in New York City. 

Both webcasts may be accessed live on the Company's website at http://www.neurocrine.com. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentations will be available on the website approximately one hour after the conclusion of each event and will be archived for one month.

Neurocrine Biosciences, Inc. is a clinical stage drug discovery company primarily focused on neurological and endocrine based diseases and disorders. The Company discovers and develops innovative pharmaceuticals, in diseases with high unmet medical needs or where the existing drug classes are inadequate, through a disciplined yet entrepreneurial process. Utilizing a portfolio approach to drug discovery, Neurocrine has multiple small molecule drug candidates at various stages of pharmaceutical development. Neurocrine's two lead late stage clinical programs are elagolix, a GnRH antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned VMAT2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences Reports Third Quarter 2013 Results
2. Neurocrine Biosciences Reports Second Quarter 2013 Results
3. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
4. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
5. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
6. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
7. Neurocrine Biosciences Reports Third Quarter 2012 Results
8. Neurocrine Biosciences Reports Second Quarter 2012 Results
9. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
10. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
11. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):